Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
New biotech company focused on cell transplantation for Parkinson’s
Biotech company Ryne Bio has received a large research grant from CIRM to develop their late-stage preclinical cell transplantation procedure for Parkinson’s.
Sun Pharma shines on c-ABL
Sun Pharma have published data on their new drug vodobatinib which is a c-ABL inhibitor – c-ABL is over-active in the brains of people with Parkinson’s.
Biotech Inhibikase develops new drug for Parkinson’s
Researchers have published laboratory data demonstrating the neuroprotective effects of a new potential drug for Parkinson’s called IkT-148009.
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Our 2022 research summary
2022 has seen Cure Parkinson’s emerge from the COVID pandemic with a bumper year of research activity; with clinical trial results being reported and exciting, innovative research projects being awarded funding. We are proud to share this end of year summary of some of these…